Abstract | BACKGROUND/AIMS: METHODS: Twenty-one patients received pioglitazone and 14 placebo in a double-blind, randomized fashion for a period of 6 months. WBF and TBW were measured before and after treatment using DXA, a water dilution technique and bioimpedance. RESULTS:
Pioglitazone increased body weight (from 93.6+/-4.2 to 96.1+/-4.5 kg, p<0.003) and WBF measured with DXA (from 32.9+/-2.1 to 35.4+/-2.5 kg, p<0.002) while no changes were seen with placebo. Total body water was not altered significantly either after pioglitazone (from 45.4+/-2.3 to 45.6+/-2.7 l, p=NS) or placebo. Muscle hydration and extracellular water were unchanged both by pioglitazone and placebo treatments. CONCLUSIONS: Six months of pioglitazone treatment in patients with NASH is associated with weight gain that is attributable to an increase in adipose tissue mass and not to water retention.
|
Authors | Bogdan Balas, Renata Belfort, Stephen A Harrison, Celia Darland, Joan Finch, Steven Schenker, Amalia Gastaldelli, Kenneth Cusi |
Journal | Journal of hepatology
(J Hepatol)
Vol. 47
Issue 4
Pg. 565-70
(Oct 2007)
ISSN: 0168-8278 [Print] Netherlands |
PMID | 17560678
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)
|
Chemical References |
- Blood Glucose
- Hypoglycemic Agents
- Thiazolidinediones
- Pioglitazone
|
Topics |
- Adipose Tissue
(drug effects)
- Blood Glucose
(drug effects)
- Body Water
(drug effects)
- Fatty Liver
(drug therapy)
- Female
- Hepatitis
(drug therapy)
- Humans
- Hypoglycemic Agents
(administration & dosage, adverse effects)
- Male
- Middle Aged
- Pioglitazone
- Thiazolidinediones
(administration & dosage, adverse effects)
- Weight Gain
|